Role of α2-Adrenoceptor Subtypes in Suppression of L-Type Ca2+ Current in Mouse Cardiac Myocytes

Sarcolemmal α2 adrenoceptors (α2-AR), represented by α2A, α2B and α2C isoforms, can safeguard cardiac muscle under sympathoadrenergic surge by governing Ca2+ handling and contractility of cardiomyocytes. Cardiomyocyte-specific targeting of α2-AR would provide cardiac muscle-delimited stress control and enhance the efficacy of cardiac malfunction treatments. However, little is known about the specific contribution of the α2-AR subtypes in modulating cardiomyocyte functions. Herein, we analyzed the expression profile of α2A, α2B and α2C subtypes in mouse ventricle and conducted electrophysiological antagonist assay evaluating the contribution of these isoforms to the suppression of L-type Ca2+ current (ICaL). Patch-clamp electro-pharmacological studies revealed that the α2-agonist-induced suppression of ICaL involves mainly the α2C, to a lesser extent the α2B, and not the α2A isoforms. RT-qPCR evaluation revealed the presence of adra2b and adra2c (α2B and α2C isoform genes, respectively), but was unable to identify the expression of adra2a (α2A isoform gene) in the mouse left ventricle. Immunoblotting confirmed the presence only of the α2B and the α2C proteins in this tissue. The identified α2-AR isoform-linked regulation of ICaL in the mouse ventricle provides an important molecular substrate for the cardioprotective targeting.


Introduction
Previously, the catalog of myocellular membrane receptors has been expanded to include α2-adrenoceptors (α2-ARs) that in line with other adrenergic receptors (α1-and β-) control the stress-reactive response of cardiomyocytes [1,2]. We have identified that, in addition to the established α2-AR-mediated feedback suppression of sympathetic and adrenal catecholamine release, α2-ARs in cardiac myocytes improve intracellular Ca 2+ handling and support myocardial contractility [2,3]. The evidence indicates that protective potential of α2-AR in cardiomyocytes can be mobilized not only against the deleterious effects of chronic stimulation by excessive catecholamine but also against angiotensinergic loads to mitigate the development of cardiac dysfunctions [1,4]. In this regard, future therapeutic directions aimed at cardiac specific restoration or enhancement of α2-AR signaling require identifying α2-AR isoforms in ventricular myocytes, which mediate cardioprotective cellular response.
To date, four different α2-AR subtypes have been identified. Mammalian species express α2A, α2B and α2C receptor isoforms encoded by the adra2A, adra2B and adra2C genes, respectively [5][6][7]. Other vertebrates, except crocodiles, also express α2D isoforms encoded by the genes adra2Da and adra2Db [8][9][10]. In mammals, primarily the α2Aand α2C-receptor subtypes are present in the central neural system, whereas all three receptor isoforms are broadly distributed in peripheral organs. The presynaptic receptor isoforms 2 of 11 exhibit different potency to norepinephrine, which is higher for the α2C-AR compared to the α2A-AR, as well as distinct responsiveness to neuronal stimulation frequencies [11][12][13]. Genetic ablations of either α2A or α2C subtypes have allowed discriminating between the α2A-AR-dependent control of plasma norepinephrine and the predominant α2C-ARdriven inhibition of the catecholamine secretion from chromaffin cells. Activation of α2B-AR mediates initial phase of peripheral hypertensive response followed by hypotension that is mediated by α2A-AR. In addition, α2B-ARs in line with other receptor isoforms also mediate the antinociceptive response to α2-AR agonists [14].
Mechanistically, activation of the presynaptic α2-ARs results in suppression of cAMP levels, opening of K + channels and inhibition of voltage-gated Ca 2+ channels directly affecting the exocytotic machinery [15,16]. Thus, α2-ARs have been recognized as short-loop feedback suppressors of sympathetic and adrenal catecholamine release and, thereby, generally have an inhibitory influence on sympathoadrenergic drive [11,[17][18][19]. The range of pharmacology effects of these receptor isoforms in neurons also relies on regulation of other than norepinephrine neurotransmitter release in the central and peripheral nervous, which contributes to anti-depressive potentials of the α2-AR antagonists [20]. Concomitantly, α2-AR agonists are clinically used as an adjuvant for premedication, especially in patients susceptible to preoperative and perioperative stress because of its sedative, anxiolytic, analgesic and sympatholytic profiles [21,22].
The expression of α2A, α2B and α2C in rat hearts was found negligible compared to levels of these receptors in neuronal, kidney, liver or aortic tissues [23], which led to the conventional belief that direct α2-AR-mediated regulation of cardiac excitation or contractile functions must be limited. More recent studies that also identified the expression of all α2-AR isoforms in rat ventricular myocytes [24,25] demonstrated that NO and cGMP were central intracellular messengers mediating α2-AR-signaling [2,25]. Key cardiomyocyte responses to activation of α2-AR include stimulation of endothelial NO synthase (eNOS), reduction of intracellular Ca 2+ levels and suppression of spontaneous intracellular Ca 2+ oscillations (presumably through the regulation of SERCA/RyR activities) and inhibition of membrane inward Ca 2+ currents via L-type Ca 2+ channels [2,25,26]. Furthermore, by promoting phosphorylation of Erk1/2, Akt and eNOS in left ventricular myocytes, the α2-AR agonist dexmedetomidine improved cardiac recovery after ischemia/reperfusion [24,27]. At the same time, the maladaptive cardiac remodeling associated with development of cardiac hypertrophy and heart failure is accompanied by the functional desensitization/internalization of α2-AR [2,28]. Comparison of the amino acid sequences in the third intracellular loop of α2-AR isoforms, the region responsible for phosphorylation of multiple serine or threonine residues, revealed little sequence homology suggesting the subtype selective desensitization mechanisms [29,30]. Thus, cardiomyocytespecific targeting of α2-ARs aimed at improving cardiac muscle-delimited stress control demands information about a link between α2-AR subtypes and specific cell-signaling pathways encompassing cardioprotective mechanisms.
While current evidence underlines a cardioprotective potential of α2-ARs in cardiomyocytes, little is known about the specific contribution of α2-AR isoforms in cardiac muscle responses. Herein we probe the expression profile of α2-AR isoforms in the mouse ventricle and analyzed the α2-AR agonist-induced suppression of L-type Ca 2+ current in isolated cardiomyocytes, using selective antagonists of α2A, α2B and α2C receptor isoforms.

Activation of α2-ARs Inhibits L-Type Ca 2+ Current
In isolated mouse cardiomyocytes guanabenz, a non-selective agonist of the α2-AR isoforms, significantly, but reversibly, reduced inward transient currents measured throughout a range of depolarizing membrane potentials (Figure 1a-c). At the applied holding potential (−40 mV) nifedipine (5 µM), a selective inhibitor of L-type Ca 2+ channels, eliminated the measured inward currents (Figure 1c). This indicates that the measured whole-cell currents represent only the low-threshold voltage-gated L-type Ca 2+ current (I CaL ) amenable to regulation by guanabenz. Dose-response relationship constructed for the effect of guanabenz on peak values of I CaL , measured at +10 mV of membrane potential, and fitted with Hill's equation revealed IC 50 = 24.8 ± 9.7 µM and h = 1.22 ± 0.38 (n = 3-5; Figure 1d,e). The time-course of guanabenz-induced inhibition of the peak I CaL values demonstrated that the steady-state blocking effect was effectively suppressed by 50 µM of yohimbine, a non-specific antagonist of α2-AR isoforms (Figure 1f). Of note, 50 µM of yohimbine alone induced 23.2 ± 3.1% inhibition of the peak I CaL values (n = 4; Figure 1f). Suppression of I CaL by guanabenz measured in the presence of yohimbine (relative to the effect of this antagonist alone) and fitted by Hill's equation demonstrated a right-shift of the guanabenz-dependent dose-response curve to IC 50 = 184.6 ± 41.3 µM and h = 1.22 ± 0.51 (n = 3-4; Figure 1e). Thus, in mouse cardiomyocytes, the activation of sarcolemmal α2-AR isoforms by guanabenz results in the suppression of I CaL . holding potential (−40 mV) nifedipine (5 µ M), a selective inhibitor of L-type Ca 2+ channels, eliminated the measured inward currents (Figure 1c). This indicates that the measured whole-cell currents represent only the low-threshold voltage-gated L-type Ca 2+ current (ICaL) amenable to regulation by guanabenz. Dose-response relationship constructed for the effect of guanabenz on peak values of ICaL, measured at +10 mV of membrane potential, and fitted with Hill's equation revealed IC50 = 24.8 ± 9.7 µ M and h = 1.22 ± 0.38 (n = 3-5; Figure 1d,e). The time-course of guanabenz-induced inhibition of the peak ICaL values demonstrated that the steady-state blocking effect was effectively suppressed by 50 µ M of yohimbine, a non-specific antagonist of α2-AR isoforms (Figure 1f). Of note, 50 µ M of yohimbine alone induced 23.2 ± 3.1% inhibition of the peak ICaL values (n = 4; Figure 1f). Suppression of ICaL by guanabenz measured in the presence of yohimbine (relative to the effect of this antagonist alone) and fitted by Hill's equation demonstrated a right-shift of the guanabenz-dependent dose-response curve to IC50 = 184.6 ± 41.3 µ M and h = 1.22 ± 0.51 (n = 3-4; Figure 1e). Thus, in mouse cardiomyocytes, the activation of sarcolemmal α2-AR isoforms by guanabenz results in the suppression of ICaL.

α2A-AR in Guanabenz-Induced Suppression of ICaL
To block the α2A receptor isoforms we applied BRL 44404, an established selective antagonist of this adrenoceptor subtype [31]. The agonist guanabenz in the presence of 40 Yohimbine, a non-specific antagonist of α2-AR isoforms, induced a rightward shift of the guanabenz-dependent dose effect. This relationship was constructed relative to the values measured in the presence of yohimbine alone. Curves represent the Hill's fits with parameters indicated in the text. (f) Representative time-course of the peak I CaL density values in the presence of guanabenz (guan) and yohimbine (yohim). Horizontal bars denote the protocol of the drug applications.

α2A-AR in Guanabenz-Induced Suppression of I CaL
To block the α2A receptor isoforms we applied BRL 44404, an established selective antagonist of this adrenoceptor subtype [31]. The agonist guanabenz in the presence of 40 µM of BRL 44408 maintained the suppression of I CaL (Figure 2a,b). BRL 44408 alone produced minor inhibition of I CaL , which was estimated at 9.4 ± 2.2% of control peak I CaL values measured at +10 mV ( Figure 2b). The antagonist BRL 44408 provided an unessential right shift of guanabenz-dependent dose-response curve, which was fitted by Hill's equation with IC 50 = 27.2 ± 4.6 µM and h = 1.34 ± 0.28 (n = 3; Figure 2c). Therefore, the α2A receptor isoform does not contribute to the suppression of I CaL.
µ M of BRL 44408 maintained the suppression of ICaL (Figure 2a,b). BRL 44408 alone produced minor inhibition of ICaL, which was estimated at 9.4 ± 2.2% of control peak ICaL values measured at +10 mV ( Figure 2b). The antagonist BRL 44408 provided an unessential right shift of guanabenz-dependent dose-response curve, which was fitted by Hill's equation with IC50 = 27.2 ± 4.6 µ M and h = 1.34 ± 0.28 (n = 3; Figure 2c). Therefore, the α2A receptor isoform does not contribute to the suppression of ICaL.

α2B-AR in Guanabenz-Induced Suppression of ICaL
To test the role of the α2B isoform in suppression of ICaL we used ARC 239, a selective antagonist of this adrenoceptor subtype [32]. ARC 239 at high concentration of 40 µ M antagonized the inhibitory effect of guanabenz on ICaL only at low doses, and, in contrast to BRL 44404, did not induce detectable effects on ICaL when applied alone (Figure 3a

α2B-AR in Guanabenz-Induced Suppression of I CaL
To test the role of the α2B isoform in suppression of I CaL we used ARC 239, a selective antagonist of this adrenoceptor subtype [32]. ARC 239 at high concentration of 40 µM antagonized the inhibitory effect of guanabenz on I CaL only at low doses, and, in contrast to BRL 44404, did not induce detectable effects on I CaL when applied alone (Figure 3a µ M of BRL 44408 maintained the suppression of ICaL (Figure 2a,b). BRL 44408 alone produced minor inhibition of ICaL, which was estimated at 9.4 ± 2.2% of control peak ICaL values measured at +10 mV ( Figure 2b). The antagonist BRL 44408 provided an unessential right shift of guanabenz-dependent dose-response curve, which was fitted by Hill's equation with IC50 = 27.2 ± 4.6 µ M and h = 1.34 ± 0.28 (n = 3; Figure 2c). Therefore, the α2A receptor isoform does not contribute to the suppression of ICaL.

α2B-AR in Guanabenz-Induced Suppression of ICaL
To test the role of the α2B isoform in suppression of ICaL we used ARC 239, a selective antagonist of this adrenoceptor subtype [32]. ARC 239 at high concentration of 40 µ M antagonized the inhibitory effect of guanabenz on ICaL only at low doses, and, in contrast to BRL 44404, did not induce detectable effects on ICaL when applied alone (Figure 3a

α2C-AR Mediates Guanabenz-Induced Suppression of I CaL
To assess the input of the α2C isoform to suppression of I CaL , the selective antagonist JP 1302 was applied [33]. While the agonistic effects of JP 1302 were not found in competition binding assays or in multiple physiological studies [33], in isolated cardiomyocytes, JP 1302 alone induced significant inhibition of I CaL (Figure 4a,b). Our measurements revealed the dose-response relationship for JP 1302-induced I CaL inhibition with IC 50 = 17.9 ± 2.7 µM and h = 1.63 ± 0.33 (n = 3-5; Figure 4c). When applied at 4 µM, JP 1302 reversed the suppression of I CaL induced by 20 µM of guanabenz (Figure 4d,e). The guanabenz doseresponse relationships constructed at 4 and 20 µM of JP 1302 indicated significant rightward shifts with IC 50 = 34.0 ± 2.3 µM, h = 1.46 ± 0.13 and IC 50 = 63.4 ± 4.8 µM, h = 1.52 ± 0.15, respectively (n = 3-4; Figure 4f). Thus, α2C is the main receptor isoform that in mouse cardiomyocytes mediates guanabenz-induced suppression of I CaL .

Expression of α2-AR Genes in Mouse Hearts
In the mouse left ventricle, RT-qPCR assay revealed low levels of α2 subtype gene expressions that might explain the necessity for relatively high agonist concentrations to induce the considerable functional output in cardiomyocyte [2,25,26]. This assay did not identify in the mouse left ventricle the expression of adra2A mRNA (α2A gene), and it revealed the mean cycle threshold values of 36.8 ± 2.7 (n = 3) for adra2B (α2В gene) and 33.9 ± 1.8 (n = 3) for adra2C (α2С gene). The ΔCt values for these genes estimated relative to the gapdh mean Ct value of 15.7 ± 0.3 (n = 6) indicate a weak expression of both mRNAs, and that the expression levels of adra2B were approximately one order of magnitude lower compared to adra2C (Figure 5a). In contrast, a more prominent expression of α2-AR isoforms was identified by this assay in the brain lysate with the mean Ct values of 25.6 ± 0.2, 28.9 ± 0.3 and 24.1 ± 0.02 for adra2A, adra2B and adra2C, respectively, and with the

Expression of α2-AR Genes in Mouse Hearts
In the mouse left ventricle, RT-qPCR assay revealed low levels of α2 subtype gene expressions that might explain the necessity for relatively high agonist concentrations to induce the considerable functional output in cardiomyocyte [2,25,26]. This assay did not identify in the mouse left ventricle the expression of adra2A mRNA (α2A gene), and it revealed the mean cycle threshold values of 36.8 ± 2.7 (n = 3) for adra2B (α2B gene) and 33.9 ± 1.8 (n = 3) for adra2C (α2C gene). The ∆Ct values for these genes estimated relative to the gapdh mean Ct value of 15.7 ± 0.3 (n = 6) indicate a weak expression of both mRNAs, and that the expression levels of adra2B were approximately one order of magnitude lower compared to adra2C (Figure 5a). In contrast, a more prominent expression of α2-AR isoforms was identified by this assay in the brain lysate with the mean Ct values of 25.6 ± 0.2, 28.9 ± 0.3 and 24.1 ± 0.02 for adra2A, adra2B and adra2C, respectively, and with the gapdh Ct value of 15.9 ± 0.1 (n = 3 for all samples). Immunoblotting demonstrated the absence of α2A protein and the presence of α2B and α2C protein subtypes in mouse left ventricle (Figure 5b).
gapdh Ct value of 15.9 ± 0.1 (n = 3 for all samples). Immunoblotting demonstrated the absence of α2A protein and the presence of α2В and α2С protein subtypes in mouse left ventricle (Figure 5b).

Discussion
We have established, herein, that in isolated mouse cardiomyocytes guanabenz, an agonist of α2-AR, reversibly suppressed L-type Ca 2+ currents. Inhibitory analysis using the specific receptor antagonists revealed that the α2-agonist-induced suppression of ICaL mainly involves the α2С, to a lesser extent the α2В, and not the α2А receptor isoforms. In general, suppression of ICaL in mouse cardiomyocytes in response to activation of α2-ARs is consistent with the data obtained in rat cardiomyocytes [2]. In both species, the intrinsic expression levels of α2-AR genes were low, which may explain the relatively low efficiency of the agonists in cardiomyocytes. However, the profile of α2-AR subtype expressions in the mouse left ventricle was found to be different from expression of corresponding mRNAs in rat cardiomyocytes. In contrast to rat cardiomyocytes, we did not identify the expression of adra2a gene in the mouse myocardium. Thus, the input of α2-AR isoforms in diverse cardiomyocyte responses may not be identical among mammals, including humans, necessitating further investigations.
The analysis of protein expression using Western blots confirmed the absence in the left mouse ventricle of the α2А isoform and the presence of the α2В and the α2С proteins. The molecular weight of the Western blot products precipitated by the antibodies against α2В protein in our study (~72 kDa), although heavier than predicted (~50 kDa), exactly correspond to the manufacturer datasheet [34]. In our studies, the Alomone Labs antibody against α2C did not precipitate any protein of the expected molecular weight. However, corresponding Abcam antibodies, in line with the manufacturer specifications, precipitated a 60-70 kDa product in the mouse tissue [35]. Of note, both the Alomone Labs and Abcam specific antibodies against the α2A receptor subtype did not detect the presence of this isoform in the lysate of mouse myocardium tissue. Although there is no clear explanation for the difference in the receptor molecular weights observed here, as well as in the manufacturer assays between mouse and, for instance, human tissues, it is possible that phosphorylation, glycosylation, lipidation, etc., may alternatively contribute to the post-translational modifications of α2-AR proteins in different tissues [36][37][38].
The specific antagonists used here are well-established tools for pharmacological discrimination of α2-AR subtypes in numerous in vivo and in vitro studies [20]. Among other specific antagonists, JP 1302, an antagonist of α2C isoform, exhibited a more significant inhibitory effect on ICaL in mouse cardiomyocytes. To the best of our knowledge, the JP 1302-induced suppression of L-type Ca 2+ currents has not been previously reported. In particular, the antagonism assays employing JP 1302 in hippocampal neurons revealed no effect of this agent alone to synaptic vesicle exocytosis, which depends upon activation of

Discussion
We have established, herein, that in isolated mouse cardiomyocytes guanabenz, an agonist of α2-AR, reversibly suppressed L-type Ca 2+ currents. Inhibitory analysis using the specific receptor antagonists revealed that the α2-agonist-induced suppression of I CaL mainly involves the α2C, to a lesser extent the α2B, and not the α2A receptor isoforms. In general, suppression of I CaL in mouse cardiomyocytes in response to activation of α2-ARs is consistent with the data obtained in rat cardiomyocytes [2]. In both species, the intrinsic expression levels of α2-AR genes were low, which may explain the relatively low efficiency of the agonists in cardiomyocytes. However, the profile of α2-AR subtype expressions in the mouse left ventricle was found to be different from expression of corresponding mRNAs in rat cardiomyocytes. In contrast to rat cardiomyocytes, we did not identify the expression of adra2a gene in the mouse myocardium. Thus, the input of α2-AR isoforms in diverse cardiomyocyte responses may not be identical among mammals, including humans, necessitating further investigations.
The analysis of protein expression using Western blots confirmed the absence in the left mouse ventricle of the α2A isoform and the presence of the α2B and the α2C proteins. The molecular weight of the Western blot products precipitated by the antibodies against α2B protein in our study (~72 kDa), although heavier than predicted (~50 kDa), exactly correspond to the manufacturer datasheet [34]. In our studies, the Alomone Labs antibody against α2C did not precipitate any protein of the expected molecular weight. However, corresponding Abcam antibodies, in line with the manufacturer specifications, precipitated a 60-70 kDa product in the mouse tissue [35]. Of note, both the Alomone Labs and Abcam specific antibodies against the α2A receptor subtype did not detect the presence of this isoform in the lysate of mouse myocardium tissue. Although there is no clear explanation for the difference in the receptor molecular weights observed here, as well as in the manufacturer assays between mouse and, for instance, human tissues, it is possible that phosphorylation, glycosylation, lipidation, etc., may alternatively contribute to the post-translational modifications of α2-AR proteins in different tissues [36][37][38].
The specific antagonists used here are well-established tools for pharmacological discrimination of α2-AR subtypes in numerous in vivo and in vitro studies [20]. Among other specific antagonists, JP 1302, an antagonist of α2C isoform, exhibited a more significant inhibitory effect on I CaL in mouse cardiomyocytes. To the best of our knowledge, the JP 1302-induced suppression of L-type Ca 2+ currents has not been previously reported. In particular, the antagonism assays employing JP 1302 in hippocampal neurons revealed no effect of this agent alone to synaptic vesicle exocytosis, which depends upon activation of both N-type and P/Q-type voltage-gated Ca 2+ currents [33,39]. JP 1302 (1-10 µM), in the absence of α2-AR agonists, exhibited no significant effects on contractile force of ventricular strips, but induced a negative inotropic effect in atrial strip samples [40]. In line with the previous studies, our results indicate that the antagonist JP 1302 hardly can be characterized as a partial α2-AR agonist, since, in this case, its effect on I CaL would be synergetic to the blocking effect of agonist. In contrast, we identified that JP 1302 at low doses could antagonize the suppression of I CaL by guanabenz. However, at present, we cannot specify the alternative α2-AR-independent mechanism by which JP 1302 affects I CaL .
We believe that the obtained results further underline the significance of α2-AR signaling that by optimizing intracellular Ca 2+ handling can increase the effectiveness of contractile systolic function and reduce a risk for detrimental Ca 2+ cellular overload [41]. Furthermore, these data provide an important molecular and genomic basis for understanding the functional reactions of myocardial cells to activation of α2-AR. Such information would be critical for a future development of animal models with a tissue-specific suppression or potentiation of expression of the α2-AR isoforms, as well as for a prospective new gene-or cell-based therapies aimed at treating cardiomyopathy and heart failure [1].

Electrophysiology
Membrane currents in isolated cardiac myocytes were measured using the perforated mode of the whole-cell patch clamp technique. Whole-cell membrane potential was controlled through the electrical access obtained by membrane patch perforation induced by amphotericin B (200-250 µg/mL) added to the pipette (4-5 MΩ) containing (in mM): CsCl, 130; MgSO 4 , 5; HEPES, 10 (pH 7.25). The bath solution contained (in mM): NaCl, 80; CaCl 2 , 2; MgSO 4 , 5; KH 2 PO 4 , 1.2; CsCl, 10; tetraethylammonium chloride (TEA-Cl), 20; glucose, 20; L-arginine, 1; HEPES, 10 (pH 7.25). L-type Ca 2+ currents were elicited by depolarizing rectangular pulses from a holding potential of −40 mV, chosen to inactivate low threshold voltage-gated channels. Currents were measured by using an Axopatch 200B amplifier (Molecular Devices, San Jose, CA, USA). Progress of membrane perforation was monitored online by estimation of serious resistance and cellular capacitance values based on analysis of capacitive transient currents. Protocol of stimulation, determination of cell parameters and data acquisition were performed by using the custom BioQuest software and a L-154 AD/DA converter (L-card, Moscow, Russia) [43]. Following formation of the perforated whole-cell patch-clamp configuration, approximately 20 MΩ of series resistances was compensated by 80-100% (at the LAG control 80-100 µs) to final values less than 12 MΩ. Measurements were performed at 31 ± 0.5 • C, using a HCC-100A temperature controller (Dagan Corp., Minneapolis, MN, USA). Peak current values measured at +10 mV of membrane potentials were normalized to the cell capacitances and presented in graphs as "Peak I CaL density".

RNA Isolation and RT-qPCR Assay
Total RNA was extracted from left ventricular walls (~100 mg) isolated from isofluorane (2%)-anesthetized mice. Tissue samples were stored and homogenized in 1 mL of ExtractRNA reagent (BC032 Evrogen, Moscow, Russia). RNA isolation was performed according to the manufacturer recommendations. At the final step, RNA was precipitated by 3 volumes of 96% ethanol. The pellet, following washing in cold 75% ethanol and air-drying, was resuspended in 100 µL of deionized water. RNA preps were treated with DNAse I (04716728001 Roche) for 1 h at 37 • C, followed by DNAse inactivation for 10 min at 70 • C, to reduce genomic DNA contamination. The quality of RNA isolation was controlled spectrophotometrically, using the NanoDrop 2000c (Thermo Fisher Scientific Inc., Waltham, MA, USA). Synthesis of cDNA was carried out with the commercially available reverse transcription MMLV RT kit (Evrogen, Moscow, Russia) using an oliogo(dT) 18 Table 1.

Data Analysis and Presentation
The averaged data are presented as mean ±SEM. Inhibition profiles of measured membrane currents in dose-response experiments were presented relative to the control current values measured before drag application and fitted with corresponding Hill's equations: where IC 50 is the half-inhibition constant, c is the concentration and h is the Hill coefficient.

Data Availability Statement:
The data presented in this study are available in the article.